Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force
- PMID: 18838717
- PMCID: PMC2731975
- DOI: 10.7326/0003-4819-149-9-200811040-00244
Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force
Abstract
Background: The U.S. Preventive Services Task Force requested a decision analysis to inform their update of recommendations for colorectal cancer screening.
Objective: To assess life-years gained and colonoscopy requirements for colorectal cancer screening strategies and identify a set of recommendable screening strategies.
Design: Decision analysis using 2 colorectal cancer microsimulation models from the Cancer Intervention and Surveillance Modeling Network.
Data sources: Derived from the literature.
Target population: U.S. average-risk 40-year-old population.
Perspective: Societal.
Time horizon: Lifetime.
Interventions: Fecal occult blood tests (FOBTs), flexible sigmoidoscopy, or colonoscopy screening beginning at age 40, 50, or 60 years and stopping at age 75 or 85 years, with screening intervals of 1, 2, or 3 years for FOBT and 5, 10, or 20 years for sigmoidoscopy and colonoscopy.
Outcome measures: Number of life-years gained compared with no screening and number of colonoscopies and noncolonoscopy tests required.
Results of base-case analysis: Beginning screening at age 50 years was consistently better than at age 60. Decreasing the stop age from 85 to 75 years decreased life-years gained by 1% to 4%, whereas colonoscopy use decreased by 4% to 15%. Assuming equally high adherence, 4 strategies provided similar life-years gained: colonoscopy every 10 years, annual Hemoccult SENSA (Beckman Coulter, Fullerton, California) testing or fecal immunochemical testing, and sigmoidoscopy every 5 years with midinterval Hemoccult SENSA testing. Annual Hemoccult II and flexible sigmoidoscopy every 5 years alone were less effective.
Results of sensitivity analysis: The results were most sensitive to beginning screening at age 40 years.
Limitation: The stop age for screening was based only on chronologic age.
Conclusion: The findings support colorectal cancer screening with the following: colonoscopy every 10 years, annual screening with a sensitive FOBT, or flexible sigmoidoscopy every 5 years with a midinterval sensitive FOBT from age 50 to 75 years.
Figures
Comment in
-
Screening guidelines for colorectal cancer: a twice-told tale.Ann Intern Med. 2008 Nov 4;149(9):680-2. doi: 10.7326/0003-4819-149-9-200811040-00247. Epub 2008 Oct 7. Ann Intern Med. 2008. PMID: 18840787 No abstract available.
-
Will test-specific adherence predict the best colorectal cancer screening strategy?Ann Intern Med. 2009 Mar 3;150(5):359; author reply 359-60. doi: 10.7326/0003-4819-150-5-200903030-00019. Ann Intern Med. 2009. PMID: 19258565 No abstract available.
Summary for patients in
-
Summaries for patients. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation.Ann Intern Med. 2008 Nov 4;149(9):I-44. doi: 10.7326/0003-4819-149-9-200811040-00246. Epub 2008 Oct 6. Ann Intern Med. 2008. PMID: 18838719 No abstract available.
Similar articles
-
Evaluating Test Strategies for Colorectal Cancer Screening—Age to Begin, Age to Stop, and Timing of Screening Intervals: A Decision Analysis of Colorectal Cancer Screening for the U.S. Preventive Services Task Force from the Cancer Intervention and Surveillance Modeling Network (CISNET) [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2009 Mar. Report No.: 08-05124-EF-2. Rockville (MD): Agency for Healthcare Research and Quality (US); 2009 Mar. Report No.: 08-05124-EF-2. PMID: 20722163 Free Books & Documents. Review.
-
Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force.Ann Intern Med. 2008 Nov 4;149(9):638-58. doi: 10.7326/0003-4819-149-9-200811040-00245. Epub 2008 Oct 6. Ann Intern Med. 2008. PMID: 18838718 Review.
-
Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force.JAMA. 2016 Jun 21;315(23):2595-609. doi: 10.1001/jama.2016.6828. JAMA. 2016. PMID: 27305518 Free PMC article.
-
Cost-effectiveness of colonoscopy in screening for colorectal cancer.Ann Intern Med. 2000 Oct 17;133(8):573-84. doi: 10.7326/0003-4819-133-8-200010170-00007. Ann Intern Med. 2000. PMID: 11033584
-
A Comparison of the Cost-Effectiveness of Fecal Occult Blood Tests with Different Test Characteristics in the Context of Annual Screening in the Medicare Population [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2003 Aug 9. Rockville (MD): Agency for Healthcare Research and Quality (US); 2003 Aug 9. PMID: 25905156 Free Books & Documents. Review.
Cited by
-
Genetic susceptibility association between viral infection and colorectal cancer risk: a two-sample Mendelian randomization analysis.Infect Agent Cancer. 2024 Aug 10;19(1):37. doi: 10.1186/s13027-024-00602-6. Infect Agent Cancer. 2024. PMID: 39123209 Free PMC article.
-
Fecal Immunochemical Test Screening and Risk of Colorectal Cancer Death.JAMA Netw Open. 2024 Jul 1;7(7):e2423671. doi: 10.1001/jamanetworkopen.2024.23671. JAMA Netw Open. 2024. PMID: 39028667 Free PMC article.
-
Optimal timing of a colonoscopy screening schedule depends on adenoma detection, adenoma risk, adherence to screening and the screening objective: A microsimulation study.PLoS One. 2024 May 24;19(5):e0304374. doi: 10.1371/journal.pone.0304374. eCollection 2024. PLoS One. 2024. PMID: 38787836 Free PMC article.
-
A qualitative interview study on colorectal cancer screening in China.Front Med (Lausanne). 2024 Jan 31;11:1232134. doi: 10.3389/fmed.2024.1232134. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38357645 Free PMC article.
-
Attitudes and Experiential Factors Associated with Completion of mt-sDNA Test Kit for Colorectal Cancer Screening.J Patient Exp. 2023 Nov 22;10:23743735231213765. doi: 10.1177/23743735231213765. eCollection 2023. J Patient Exp. 2023. PMID: 38026067 Free PMC article.
References
-
- Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer. 2004;101:3–27. [PMID: 15221985] - PubMed
-
- American Cancer Society . Cancer Facts and Figures 2008. Accessed at www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf on September 15, 2008.
-
- Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328:1365–71. [PMID: 8474513] - PubMed
-
- Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472–7. [PMID: 8942775] - PubMed
-
- Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348:1467–71. [PMID: 8942774] - PubMed
Publication types
MeSH terms
Grants and funding
- U01 CA115953/CA/NCI NIH HHS/United States
- U01 CA097426/CA/NCI NIH HHS/United States
- U01 CA097426-07/CA/NCI NIH HHS/United States
- P30 CA008748/CA/NCI NIH HHS/United States
- HHSP233200700196P/PHS HHS/United States
- U01 CA115953-04/CA/NCI NIH HHS/United States
- HHSP233200700350P/PHS HHS/United States
- U01-CA-115953/CA/NCI NIH HHS/United States
- U01 CA088204-07/CA/NCI NIH HHS/United States
- U01-CA-088204/CA/NCI NIH HHS/United States
- U01 CA088204/CA/NCI NIH HHS/United States
- HHSP233200700210P/PHS HHS/United States
- U01-CA-097426/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials